Citius Pharmaceuticals (CTXR) Net Income towards Common Stockholders (2010 - 2026)

Citius Pharmaceuticals (CTXR) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$21.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 94.49% year-over-year to -$21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.2 million (down 7.21% YoY) and the FY2025 annual result came in at -$37.4 million, up 6.85% from the prior year.
• Net Income towards Common Stockholders eased to -$21.2 million in Q1 2026, from -$8.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$3.6 million in Q4 2022 to a low of -$21.2 million in Q1 2026.
• A 5-year average of -$9.7 million and a median of -$8.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 61.05% — and 2023, when it plunged 156.88%.
• Tracing CTXR's Net Income towards Common Stockholders over 5 years: stood at -$3.6 million in 2022, then sank by 156.88% to -$9.2 million in 2023, then decreased by 5.82% to -$9.8 million in 2024, then climbed by 15.84% to -$8.2 million in 2025, then plunged by 158.26% to -$21.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$21.2 million (Q1 2026), -$8.2 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.